Table 4.
Procedural and clinical characteristics of patients who experienced cellulitis or reconstruction failure
| Characteristic | Cellulitis | Implant removal | P-value |
|---|---|---|---|
| Total number | 34 (58.6) | 24 (41.4) | - |
| Direct to implant | 22 (78.6) | 6 (21.4) | 0.0029 |
| Tissue expander | 12 (40.0) | 18 (60.0) | |
| Median age (yr) | 44.9 (34–69) | 46.4 (18–83) | 0.5451 |
| Body mass index (kg/m2) | 22.0 (19.2–29.1) | 21.4 (18.2–25.9) | 0.4027 |
| Onset time of infection | 20 (5–150) | 16.5 (3–191) | 0.3201 |
| Neoadjuvant CTx | 7 (20.59) | 2 (8.33) | 0.2816 |
| Adjuvant CTx | 12 (35.29) | 13 (54.17) | 0.1529 |
| Adjuvant RTx | 9 (26.47) | 7 (29.17) | 0.8210 |
| HTN | 5 (14.71) | 4 (16.67) | 0.9999 |
| DM | 3 (8.82) | 1 (4.17) | 0.6351 |
| Smoking Hx | 1 (2.94) | 2 (8.33) | 0.5637 |
| ADM use | 25 (73.53) | 15 (62.5) | 0.3712 |
| Axillary node dissection | 16 (47.06) | 13 (54.17) | 0.5939 |
| HV removal date #1 (POD) | 11 (3–40) | 18 (5–38) | 0.0433 |
| HV removal date #2 (POD) | 16.5 (3–52) | 20 (5–29) | 0.8642 |
Values are presented as median (range) or number (%).
CTx, chemotherapy; RTx, radiotherapy; HTN, hypertension; DM, diabetes mellitus; Hx, history; ADM, acellular dermal matrix; HV, Hemovac; POD, postoperative day.